Immunoglobulin M (IgM) is also one of the first antibodies recruited by the immune system to fight infection. IgM populations rise very quickly when the body is first confronted with an infectious ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The company’s shares closed last Wednesday at $6.20 ...

Stifel downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company’s “surprising decision” to discontinue all further ...

Late this week, a quartet of companies—IGM Biosciences, Y-mAbs Therapeutics, Passage Bio and Shoreline Biosciences—each revealed plans to cut jobs as they rework their respective pipelines and ...

Should be unloaded only during working hours. The importer of the goods should file a bill of entry (customs copy) electronically for the clearance of the goods, before or on arrival of the goods. In ...

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...